Tiago R. Matos has a longstanding interest in cellular immunology, particularly the interaction of T cells between human tissues and its relation to human autoimmune and inflammatory disorders. After graduating, in 2013, from his Master's and Medical degree with honors (MD, MSc), he received a Harvard Medical School scholarship that allowed him to conduct research at the laboratory of Prof. Dr. Jerome Ritz (Medical Oncology/Hematology at Dana Farber Cancer Institute/Harvard Medical School).
His pioneer translation research on regulatory T cells(Treg), has shown that humans have since birth a highly heterogenic subpopulations of Treg(both maturation and phenotypic subsets), which increase during our childhood and are essential to suppress the wide range of effector cells through several mechanisms. Treg heterogeneity seems to also be essential after hematopoietic stem cell transplantation(HSCT), being affected during graft-versus-host disease(GVHD). He helped to characterize the immunological impact of novel and successful therapies for GVHD in clinical trials, such as low-dose interleukin 2(IL-2) or with antibodies conjugated to an immunotoxin(CD3/CD7-ricin A).